



CORRECTION

## Correction to: The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants

Joseph Chen · Huiping Xu · Sylvester Pawlak · Leonard P. James · Gerson Peltz · Kimberly Lee · Katherine Ginman · Michelle Bergeron · Yazdi K. Pithavala

Published online: September 10, 2020  
© Springer Healthcare Ltd., part of Springer Nature 2020

Correction to: Adv Ther (2020) 37:745–758  
<https://doi.org/10.1007/s12325-019-01198-9>

In the original article, the reference 4 has been published and cited incorrectly. The correct reference 4 is “Lorbrena<sup>®</sup> (lorlatinib) tablets. [Prescribing Information]. Pfizer Labs”. Additionally, reference 4 was cited in error in the Discussion section of the original article (page

755, column 2, paragraph 2, sentence 1). The corrected sentence is as follows: “When used in drug-drug interaction studies to elicit metabolic induction, a rifampin dose of 600 mg/day is typically not associated with transaminase elevations [7, 10].”

---

The original article can be found online at <https://doi.org/10.1007/s12325-019-01198-9>.

---

J. Chen (✉) · L. P. James  
Global Product Development, Pfizer Oncology, New York, NY, USA  
e-mail: joseph.chen@pfizer.com

H. Xu · Y. K. Pithavala  
Global Product Development, Clinical Pharmacology, Pfizer Oncology, La Jolla, CA, USA

S. Pawlak  
Global Product Development, Pfizer Inc., New Haven, CT, USA

G. Peltz  
Safety Surveillance and Risk Management, Pfizer Oncology, Groton, CT, USA

K. Lee · M. Bergeron  
Global Product Development, Pfizer Inc., Groton, CT, USA

K. Ginman  
Global Product Development, Pfizer Inc., South Lyon, MI, USA